Pfizer Halts Research Into Alzheimer’s And Parkinson’s Treatments.
Pfizer has announced plans to end its research efforts to discover new drugs for Alzheimer’s and Parkinson’s diseases.
The pharmaceutical giant explained its decision, which will entail roughly 300 layoffs, as a move to better position itself “to bring new therapies to patients who need them.”
“As a result of a recent comprehensive review, we have made the decision to end our neuroscience discovery and early development efforts and re-allocate [spending] to those areas where we have strong scientific leadership and that will allow us to provide the greatest impact for patients,” Pfizer said in a statement emailed to NPR.
Pfizer added that it will “continue to fully support” development on tanezumab and Lyrica, two treatments targeting chronic pain, as well as programs researching rare neurological diseases.
The round of several hundred layoffs “will take place over the coming months” at its research and development labs in the Northeast — specifically, sites in Cambridge and Andover, Mass., and in Groton, Conn.
The Two-Way : NPR
Pfizer to Stall R&D for Alzheimer’s/Parkinson’s, Cut Jobs – January 8, 2018 – Zacks.com
Alzheimer’s takes Another Hit as Pfizer Ends Research in this Area – January 8, 2018 – Zacks.com